COV-CML UK Retrospective Data For COVID-19/SARS-CoV-2 in CML [COVID-19]
Research type
Research Study
Full title
COV-CML\nUK National Retrospective Data Collection For COVID-19 Disease / SARS-CoV-2 Infection in CML Patients
IRAS ID
286624
Contact name
Dragana Milojkovic
Contact email
Sponsor organisation
AHSC Joint Research Compliance Office
Duration of Study in the UK
1 years, 5 months, 17 days
Research summary
Patients with cancer may be more vulnerable to SARS-CoV-2-infection and to develop coronavirus disease 2019 (COVID-19) compared with unaffected individuals. It is unclear if this increased risk applies to all cancer types. One study of 125 hospitalised patients with haematological cancers had a 10 percent incidence of COVID-19 but none of these cases had chronic myeloid leukaemia (CML). This study will evaluate prevalence and clinical features of COVID-19 in CML patients during the SARS-CoV-2 pandemic. \n\nPatients with haematological malignancies are seen as a vulnerable population in regards to expected outcomes following SARS-CoV-2 infection. This study aims to follow the course of the COVID-19 disease in patients with chronic myeloid leukaemia and estimate the incidence of COVID-19 disease and SARS-CoV-2 infection in this patient cohort. \n\nThis is a retrospective questionnaire study addressing the incidence and course of SARS-CoV-2 infection in reported CML patients with clinically suspected COVID-19 disease or confirmed SARS-CoV-2 viral infection. \n\nThe gravity of the current SARS-CoV-2 pandemic justifies the effort needed to undertake this study. \nThe study will analyse the medical data of up to 100 patients from the two sites in the United Kingdom. \nThe study is expected to start on 15.07.2020 and be concluded by 31.12.2021. \nThe study will be run in two major CML treatment centres in the UK, at the Hammersmith Hospital of Imperial College Healthcare NHS Trust in London, England, and at the Paul O’Gorman Leukaemia Research Centre of the Gartnavel General Hospital in Glasgow, Scotland.\nThe exact data that will be collected in the form of the CML COVID-19 questionnaire is shown in Appendix 1. \nNo interim analyses are planned. The data will be analysed only when the full dataset has been collected, from 100 participants. Data collection, analysis, and interpretation will be concluded by December 2021.
REC name
N/A
REC reference
N/A